[Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Patients with malignant skin melanoma were given different kinds of immunotherapy; nonspecific immunotherapy with BCG vaccine, adaptive immunotherapy with methotrexate or phytohemagglutinin activated autolymphocytes, and also a combination of polychemotherapy with BCG. The state of cell immunity was determined prior to, during and at the end of the therapy, in accordance with the courses. As a result of the conducted therapy an increased level of cell immunity was observed, that usually corresponded to clinical development of the disease. At the same time, the increase in immune response indices due to continuous administration of BCG vaccine is not related with the clinical course, while the persistent anergy or reduced level of cell immunity during this kind of therapy is a poor prognostic sign.
D000937:Antigen-Antibody Reactions; D001500:BCG Vaccine / Q000008:administration & dosage; D004137:Dinitrochlorobenzene; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D037102:Lectins / Q000032:analysis; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D008727:Methotrexate / Q000276:immunology; D012008:Recurrence; D012075:Remission, Spontaneous; D012397:Rosette Formation; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy; D012882:Skin Tests; D014374:Tuberculin Test
D001500:BCG Vaccine; D004137:Dinitrochlorobenzene; D037102:Lectins; D008727:Methotrexate
Immunologicheskie reaktsii bol'nykh melanomoĭ kozhi pri nespetsificheskoĭ i adoptivnoĭ immunoterapii.